Wedbush Reaffirms Outperform Rating for Perspective Therapeutics (NYSE:CATX)

Perspective Therapeutics (NYSE:CATX)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a report issued on Friday,RTT News reports. They currently have a $11.00 price target on the stock. Wedbush’s price objective would suggest a potential upside of 174.31% from the company’s current price.

Several other equities research analysts have also commented on CATX. Bank of America lowered shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the company from $24.00 to $5.00 in a research note on Monday, November 25th. Oppenheimer reduced their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, November 22nd. Royal Bank of Canada reissued an “outperform” rating and issued a $16.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Finally, UBS Group assumed coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 target price for the company. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $15.14.

Perspective Therapeutics Price Performance

Shares of Perspective Therapeutics stock traded up $0.38 during mid-day trading on Friday, hitting $4.01. 1,730,130 shares of the stock were exchanged, compared to its average volume of 1,172,306. Perspective Therapeutics has a twelve month low of $2.70 and a twelve month high of $19.05. The company has a 50-day simple moving average of $3.68 and a 200 day simple moving average of $9.76.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21). The firm had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. Equities analysts predict that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Insider Buying and Selling at Perspective Therapeutics

In related news, CEO Johan M. Spoor acquired 8,000 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were bought at an average cost of $3.77 per share, with a total value of $30,160.00. Following the completion of the acquisition, the chief executive officer now owns 36,257 shares of the company’s stock, valued at $136,688.89. This trade represents a 28.31 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Jonathan Robert Hunt bought 12,829 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were bought at an average price of $3.82 per share, with a total value of $49,006.78. Following the transaction, the chief financial officer now directly owns 48,800 shares in the company, valued at $186,416. This trade represents a 35.66 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 67,570 shares of company stock valued at $256,789 in the last quarter. Corporate insiders own 3.52% of the company’s stock.

Institutional Investors Weigh In On Perspective Therapeutics

Several large investors have recently made changes to their positions in CATX. nVerses Capital LLC acquired a new stake in shares of Perspective Therapeutics in the third quarter valued at $57,000. Trueblood Wealth Management LLC raised its stake in shares of Perspective Therapeutics by 37.0% in the fourth quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company’s stock worth $71,000 after acquiring an additional 6,000 shares during the last quarter. Koa Wealth Management LLC bought a new stake in shares of Perspective Therapeutics during the fourth quarter valued at approximately $83,000. SG Americas Securities LLC increased its holdings in shares of Perspective Therapeutics by 41.3% in the fourth quarter. SG Americas Securities LLC now owns 26,088 shares of the company’s stock valued at $83,000 after purchasing an additional 7,627 shares in the last quarter. Finally, US Bancorp DE raised its position in Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after purchasing an additional 3,866 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.